NEW YORK (GenomeWeb) – Mayo Medical Laboratories will collaborate with Advanced Biological Laboratories to develop a next-generation sequencing pipeline for laboratory-developed diagnostic tests.

Under the terms of agreement, the Mayo Clinic Division of Clinical Microbiology will select the clinical samples on which the tests will be validated, while ABL will lead development of information technology. ABL is a Luxembourg-based medical data technology company that develops information technology and health solutions for patient management and sequencing data analysis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.